173 related articles for article (PubMed ID: 33346501)
1. [Nephrotoxicity of anti-angiogenesis drugs].
Grechukhina KS; Chebotareva NV; Krasnova TN
Ter Arkh; 2020 Jul; 92(6):93-98. PubMed ID: 33346501
[TBL] [Abstract][Full Text] [Related]
2. [Angiogenesis inhibitors: mechanism of action and nephrotoxicity].
Clou E; Luque Y
Nephrol Ther; 2022 Feb; 18(1):1-6. PubMed ID: 34838486
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature.
Usui J; Glezerman IG; Salvatore SP; Chandran CB; Flombaum CD; Seshan SV
Hum Pathol; 2014 Sep; 45(9):1918-27. PubMed ID: 25087655
[TBL] [Abstract][Full Text] [Related]
4. Nephrotoxicity induced by intravitreal vascular endothelial growth factor inhibitors: emerging evidence.
Hanna RM; Barsoum M; Arman F; Selamet U; Hasnain H; Kurtz I
Kidney Int; 2019 Sep; 96(3):572-580. PubMed ID: 31229276
[TBL] [Abstract][Full Text] [Related]
5. Renal effects of anti-angiogenesis therapy: update for the internist.
Gurevich F; Perazella MA
Am J Med; 2009 Apr; 122(4):322-8. PubMed ID: 19332223
[TBL] [Abstract][Full Text] [Related]
6. Exploring the Benefit/Risk Associated with Antiangiogenic Agents for the Treatment of Non-Small Cell Lung Cancer Patients.
Kurzrock R; Stewart DJ
Clin Cancer Res; 2017 Mar; 23(5):1137-1148. PubMed ID: 27940520
[TBL] [Abstract][Full Text] [Related]
7. Anti-VEGF-related thrombotic microangiopathy in a child presenting with nephrotic syndrome.
Yılmaz S; Özçakar ZB; Taktak A; Kiremitçi S; Ensari A; Dinçaslan H; Yalçınkaya F
Pediatr Nephrol; 2016 Jun; 31(6):1029-32. PubMed ID: 26928310
[TBL] [Abstract][Full Text] [Related]
8. Antiangiogenic therapy for high-grade glioma.
Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N
Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542
[TBL] [Abstract][Full Text] [Related]
9. Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy.
Shinkaruk S; Bayle M; Laïn G; Déléris G
Curr Med Chem Anticancer Agents; 2003 Mar; 3(2):95-117. PubMed ID: 12678905
[TBL] [Abstract][Full Text] [Related]
10. Anti-Angiogenic Drugs, Vascular Toxicity and Thromboembolism in Solid Cancer.
Riondino S; Del Monte G; Fratangeli F; Guadagni F; Roselli M; Ferroni P
Cardiovasc Hematol Agents Med Chem; 2017; 15(1):3-16. PubMed ID: 28137223
[TBL] [Abstract][Full Text] [Related]
11. Antiangiogenic Therapy for Diabetic Nephropathy.
Tanabe K; Maeshima Y; Sato Y; Wada J
Biomed Res Int; 2017; 2017():5724069. PubMed ID: 28835895
[TBL] [Abstract][Full Text] [Related]
12. Vascular endothelial growth factor inhibitors in colon cancer.
Díaz-Rubio E
Adv Exp Med Biol; 2006; 587():251-75. PubMed ID: 17163170
[TBL] [Abstract][Full Text] [Related]
13. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
Zhao Y; Adjei AA
Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
[TBL] [Abstract][Full Text] [Related]
14. Renal-limited thrombotic microangiopathy after switching from bevacizumab to ramucirumab: a case report.
Yamada R; Okawa T; Matsuo K; Suzuki M; Mori N; Mori K
BMC Nephrol; 2019 Jan; 20(1):14. PubMed ID: 30634936
[TBL] [Abstract][Full Text] [Related]
15. Dual blockade of VEGFR1 and VEGFR2 by a novel peptide abrogates VEGF-driven angiogenesis, tumor growth, and metastasis through PI3K/AKT and MAPK/ERK1/2 pathway.
Sadremomtaz A; Mansouri K; Alemzadeh G; Safa M; Rastaghi AE; Asghari SM
Biochim Biophys Acta Gen Subj; 2018 Dec; 1862(12):2688-2700. PubMed ID: 30251659
[TBL] [Abstract][Full Text] [Related]
16. [Clinical and laboratory signs and risk factors for nephrotoxicity, associated with antiangiogenic drugs].
Grechukhina KS; Chebotareva NV; Zhukova LG; Krasnova TN
Ter Arkh; 2021 Jun; 93(6):661-666. PubMed ID: 36286831
[TBL] [Abstract][Full Text] [Related]
17. Tumor angiogenesis and accessibility: role of vascular endothelial growth factor.
Jain RK
Semin Oncol; 2002 Dec; 29(6 Suppl 16):3-9. PubMed ID: 12516032
[TBL] [Abstract][Full Text] [Related]
18. Antiangiogenic therapy for high-grade gliomas.
Chamberlain MC; Raizer J
CNS Neurol Disord Drug Targets; 2009 Jun; 8(3):184-94. PubMed ID: 19601816
[TBL] [Abstract][Full Text] [Related]
19. Hypertension and proteinuria: a class-effect of antiangiogenic therapies.
Launay-Vacher V; Deray G
Anticancer Drugs; 2009 Jan; 20(1):81-2. PubMed ID: 19343005
[TBL] [Abstract][Full Text] [Related]
20. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications.
Ferrara N
Semin Oncol; 2002 Dec; 29(6 Suppl 16):10-4. PubMed ID: 12516033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
